Efficient induction of T helper type 1-mediated immune responses in antigen-primed mice by anti-CD3 single-chain Fv/interleukin-18 fusion DNA

Immunology

Volumn 111, Issue 1, 2004, Pages 27-34

  Kim, E J ^a   Cho, D ^b   Kim, T S ^a  

^a Chonnam National University   (South Korea)

^b Sookmyung Women's University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD3 ANTIGEN; CD3 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; COMPLEMENTARY DNA; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INTERLEUKIN 18; INTERLEUKIN 4; OVALBUMIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; COVALENT BOND; CYTOKINE PRODUCTION; FUSION GENE; IMMUNE RESPONSE; INHIBITION KINETICS; INJECTION; MAMMAL; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SENSITIZATION; TH1 CELL; VACCINATION;

ALLERGENS; ANIMALS; ANTIGENS, CD3; DNA; FEMALE; HELA CELLS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; INTERLEUKIN-18; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; OVALBUMIN; RECOMBINANT FUSION PROTEINS; TH1 CELLS;

EID: 0347555461     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2004.01784.x     Document Type: Article

References (39)

1. + T cells. Immunol Rev 1991; 123:209-29.
2. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 2002; 14:1693-711.
3. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996; 80:225-35.
4. Spellberg B, Edwards JE Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001; 32:76-102.
5. + T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15:297-322.
6. Gorham JD, Guler ML, Steen RG, Mackey AJ, Daly MJ, Frederick K, Dietrich WF, Murphy KM. Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses. Proc Natl Acad Sci USA 1996; 93:12467-72.
7. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003; 21:713-58.
8. Nakamura K, Okamura H, Nagata K, Komatsu T, Tamura T. Purification of a factor which provides a costimulatory signal for γ interferon production. Infect Immun 1993; 61:64-70.
9. Gu Y, Kuida K, Tsutsui H et al. Activation of interferon-γ inducing factor mediated by interleukin-1γ converting enzyme. Science 1997; 275:206-9.
10. Dinarello CA. Interleukin-18. Methods 1999; 19:121-32.
11. Hara S, Nagai H, Miyake H, Yamanaka K, Arakawa S, Ichihashi M, Kamidono S, Hara I. Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity. J Urol 2001; 165:2039-43.
12. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998; 70:281-312.
13. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19:423-74.
14. Xu D, Liew FY. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 1995; 84:173-6.
15. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization. Annu Rev Immunol 2000; 18:927-74.
16. Jiang W, Pisetsky DS. Enhancing immunogenicity by CpG DNA. Curr Opin Mol Ther 2003; 5:180-5.
17. Liu MA. DNA vaccines: a review. J Intern Med 2003; 253:169-78.
18. Kim EJ, Cho D, Hwang SY, Kim TS. Interleukin-2 fusion protein with anti-CD3 single-chain Fv (sFv) selectively protects T cells from dexamethasone-induced apoptosis. Vaccine 2001; 20:608-15.
19. Reff ME, Garner K, Chambers KS et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45.
20. Colligan JE, Kruisbeek AM, Margulies DH, Shevvach EM, Strober W. Current Protocols in Immunology. New York: John Wiley & Sons, 1991.
21. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8.
22. + T cells through an effect on antigen-presenting cells. J Immunol 1995; 154:2578-87.
23. Kim TS, DeKyuyff RH, Rupper R, Maecker HT, Levy S, Umetsu DT. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997; 158:4137-44.
24. Bohn E, Sing A, Zumbihl R, Bielfeldt C, Okamura H, Kurimoto M, Heesemann J, Autenrieth IB. IL-18 (IFN-γ-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol 1998; 160:299-307.
25. Danko I, Wolff JA. Direct gene transfer into muscle. Vaccine 1994; 12:1499-502.
26. Whitton JL, Yokoyama M. Proteins expressed by DNA vaccines induce both local and systemic immune responses. Ann N Y Acad Sci 1996; 797:196-206.
27. Pertmer TM, Roberts TR, Haynes JR. Influenza virus nucleoprotein- specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 1996; 70:6119-25.
28. Yokoyama M, Hassett DE, Zhang J, Whitton JL. DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site. Vaccine 1997; 15:553-60.
29. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol 1998; 161:3400-7.
30. Chang JT, Segal BM, Nakanishi K, Okamura H, Shevach EM. The costimulatory effect of IL-18 on the induction of antigen-specific IFN-γ production by resting T cells is IL-12 dependent and is mediated by up-regulation of the IL-12 receptor β2 subunit. Eur J Immunol 2000; 30:1113-9.
31. Heuer JC, Tucker-McClung C, Hock RA. Neuroblastoma cells expressing mature IL-18, but not pro IL-18, induce a strong and immediate antitumor immune response. J Immunother 1999; 22:324-35.
32. Kremer L, Dupre L, Wolowczuk I, Locht C. In vivo immunomodulation following intradermal injection with DNA encoding IL-18. J Immunol 1999; 163:3226-31.
33. Kim SH, Cho D, Kim TS. Induction of in vivo persistent resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18. Immunology 2001; 102:234-41.
34. Gillies SD, Young D, Lo KM, Roberts S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconj Chem 1993; 4:230-5.
35. Tsuji-Takayama K, Aizawa Y, Okamoto I et al. Interleukin-18 induces interferon-γ production through NF-κB and NF-AT activation in murine T helper type 1 cells. Cell Immunol 1999; 196:41-50.
36. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 1996; 23:101-7.
37. Tasaki K, Yoshida Y, Maeda T et al. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Ther 2000; 7:247-54.
38. Sugaya M, Nakamura K, Tamaki K. Interleukins 18 and 12 synergistically upregulate interferon-γ production by murine dendritic epidermal T cells. J Invest Dermatol 1999; 113:350-4.
39. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T, Okamura H, Nakanishi K. IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells. Int Immunol 2000; 12:151-60.